- Home
- Publications
- Publication Search
- Publication Details
Title
New Perspectives on Antimicrobial Agents: Cefiderocol
Authors
Keywords
-
Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 65, Issue 8, Pages -
Publisher
American Society for Microbiology
Online
2021-05-21
DOI
10.1128/aac.02171-20
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Synergistic rifabutin and colistin reduce emergence of resistance when treating Acinetobacter baumannii
- (2021) Jiaqi Cheng et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic
- (2021) Ana Paula Streling et al. CLINICAL INFECTIOUS DISEASES
- It’s Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa
- (2021) Payam Behzadi et al. Antibiotics-Basel
- Salvage Treatment with Cefiderocol Regimens in Two Intravascular Foreign Body Infections by MDR Gram-Negative Pathogens, Involving Non-Removable Devices
- (2021) Marta Bodro et al. Infectious Diseases and Therapy
- Avibactam potentiated the activity of both ceftazidime and aztreonam against S. maltophilia clinical isolates in vitro
- (2021) Qiuxia Lin et al. BMC MICROBIOLOGY
- Case Commentary: the Need for Cefiderocol Is Clear, but Are the Supporting Clinical Data?
- (2020) Ryan K. Shields ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
- (2020) Kenneth V.I. Rolston et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
- (2020) Renee Ackley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacilli Isolated from Patients in Canadian Intensive Care Units
- (2020) Alyssa R. Golden et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
- (2020) David van Duin et al. LANCET INFECTIOUS DISEASES
- Structural basis of reduced susceptibility to ceftazidime–avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion
- (2020) Akito Kawai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime
- (2020) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- Cefiderocol for extensively-drug resistant gram-negative bacterial infections: real-world experience from a case-series and review of the literature
- (2020) Sandra Zingg et al. Open Forum Infectious Diseases
- Case Report: Successful Rescue Therapy of Extensively Drug-Resistant Acinetobacter baumannii Osteomyelitis With Cefiderocol
- (2020) Michael Dagher et al. Open Forum Infectious Diseases
- Carbapenemases: Transforming Acinetobacter baumannii into a Yet More Dangerous Menace
- (2020) Maria Soledad Ramirez et al. Biomolecules
- Cefiderocol Antimicrobial Susceptibility Testing Considerations: The Achilles Heel of the Trojan Horse?
- (2020) Patricia J. Simner et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Combining bacteriophages with cefiderocol and meropenem/vaborbactam to treat a pan‐drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient
- (2020) Andrew B. Gainey et al. PEDIATRIC PULMONOLOGY
- An Overview of the Treatment of Less Common Non‐Lactose Fermenting Gram Negative Bacteria
- (2020) Hannah K. Spencer et al. PHARMACOTHERAPY
- A nutrient-limited screen unmasks rifabutin hyperactivity for extensively drug-resistant Acinetobacter baumannii
- (2020) Brian Luna et al. Nature Microbiology
- Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-Negative infections in ICU patients
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms
- (2020) Vincent Trebosc et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-negative Bacilli: A Comparison of Disk Diffusion to Broth Microdilution
- (2020) C. Paul Morris et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- (2020) Richard G Wunderink et al. LANCET INFECTIOUS DISEASES
- Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively- and pan-resistant Acinetobacter baumannii
- (2020) A. Oliva et al. Journal of Global Antimicrobial Resistance
- Compassionate Use of Cefiderocol to Treat a Case of Prosthetic Joint Infection Due to Extensively Drug-Resistant Enterobacter hormaechei
- (2020) Soline Siméon et al. Microorganisms
- Cefiderocol Retains Antibiofilm Activity in Multidrug-Resistant Gram-Negative Pathogens
- (2020) Christine A. Pybus et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Minocycline alone and in combination with polymyxin B, meropenem, and sulbactam against carbapenem- susceptible and resistant Acinetobacter baumannii in in vitro pharmacodynamic model
- (2020) Maya Beganovic et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection
- (2020) Nao Kawaguchi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol for the Treatment of Adult and Pediatric Patients with Cystic Fibrosis and Achromobacter xylosoxidans Infections
- (2020) Nathaniel C Warner et al. CLINICAL INFECTIOUS DISEASES
- Susceptibility of Elizabethkingia spp. to commonly tested and novel antibiotics and concordance between broth microdilution and automated testing methods
- (2020) Shu-Chen Kuo et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cefiderocol in the treatment of systemic carbapenemase-producing multidrug-resistant Klebsiella pneumoniae infection
- (2020) Temi Lampejo et al. Journal of Global Antimicrobial Resistance
- Recurrent neurosurgical site infection by extensively drug-resistant P. aeruginosa treated with cefiderocol: a case report and literature review
- (2020) Davide Fiore Bavaro et al. Infectious Diseases
- Variations in the Occurrence of Resistance Phenotypes and Carbapenemase Genes Among Enterobacteriaceae Isolates in 20 Years of the SENTRY Antimicrobial Surveillance Program
- (2019) Mariana Castanheira et al. Open Forum Infectious Diseases
- Reproducibility of broth microdilution MICs for the novel Siderophore cephalosporin, Cefiderocol, determined using Iron-depleted cation-adjusted Mueller-Hinton broth
- (2019) Meredith A. Hackel et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- The Infectious Diseases Society of America’s 10 × ’20 Initiative (Ten New Systemic Antibacterial Agents FDA-approved by 2020): Is 20 × ’20 a Possibility?
- (2019) George H Talbot et al. CLINICAL INFECTIOUS DISEASES
- In vivo pharmacodynamic study of cefiderocol, a novel parenteral siderophore cephalosporin, in murine thigh and lung infection models
- (2019) Rio Nakamura et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics-pharmacodynamics of β-lactamase inhibitors: are we missing the target?
- (2019) Marguerite L Monogue et al. Expert Review of Anti-Infective Therapy
- Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report
- (2019) Enrico Maria Trecarichi et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Co-Infections of Two Strains of NDM-1 and OXA-232 Co-producing Klebsiella pneumoniae in a Kidney Transplant Patient
- (2019) Deisy A. Contreras et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa
- (2019) Jason M Pogue et al. CLINICAL INFECTIOUS DISEASES
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
- (2019) Johann Motsch et al. CLINICAL INFECTIOUS DISEASES
- Compassionate use of cefiderocol in the treatment of an intraabdominal infection due to multidrug resistant Pseudomonas aeruginosa : A case report
- (2019) Ryan W. Stevens et al. PHARMACOTHERAPY
- Polymyxin susceptibility testing and interpretive breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST)
- (2019) Jason M. Pogue et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activities of β-Lactam–β-Lactamase Inhibitor Antimicrobial Agents against Cystic Fibrosis Respiratory Pathogens
- (2019) Lindsay J. Caverly et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- The Role of Iron and Siderophores in Infection, and the Development of Siderophore Antibiotics
- (2019) Malcom G P Page CLINICAL INFECTIOUS DISEASES
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
- (2019) Yoshinori Yamano CLINICAL INFECTIOUS DISEASES
- Long Term Compassionate Use of Cefiderocol to Treat Chronic Osteomyelitis Caused by XDR-Pseudomonas aeruginosa and ESBL-producing Klebsiella pneumoniae in a Pediatric Patient
- (2019) Zain I. Alamarat et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Successful Treatment of Persistent Burkholderia cepacia Complex Bacteremia with Ceftazidime-Avibactam
- (2018) Pranita D. Tamma et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Ceftazidime-Avibactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa Collected in Asia-Pacific Countries: Results from the INFORM Global Surveillance Program, 2012 to 2015
- (2018) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- TonB-Dependent Receptor Repertoire of Pseudomonas aeruginosa for Uptake of Siderophore-Drug Conjugates
- (2018) Alexandre Luscher et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics, Safety, and Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative Bacteria, in Healthy Subjects
- (2018) Yutaka Saisho et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Role of association of OmpK35 and OmpK36 alteration and bla ESBL and/or bla AmpC genes in conferring carbapenem resistance among non-carbapenemase-producing Klebsiella pneumoniae
- (2018) Zaineb Hamzaoui et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Analysis of Potential β-Lactam Surrogates To Predict In Vitro Susceptibility and Resistance to Ceftaroline for Clinical Isolates of Enterobacteriaceae
- (2018) Meredith A. Hackel et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Interdependence between iron acquisition and biofilm formation in Pseudomonas aeruginosa
- (2018) Donghoon Kang et al. JOURNAL OF MICROBIOLOGY
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
- (2018) Mical Paul et al. LANCET INFECTIOUS DISEASES
- Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient
- (2018) Vasilios Athans et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Compassionate Use of Cefiderocol as Adjunctive Treatment of Native Aortic Valve Endocarditis Due to Extremely Drug-resistant Pseudomonas aeruginosa
- (2018) Jonathan D Edgeworth et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Activity of Cefiderocol, a Siderophore Cephalosporin, Against Gram-Negative Bacilli Isolated by Clinical Laboratories in North America and Europe in 2015-2016: SIDERO-WT-2015
- (2018) James A. Karlowsky et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
- (2018) Krystyna M. Kazmierczak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
- (2018) Simon Portsmouth et al. LANCET INFECTIOUS DISEASES
- Prevalence of different carbapenemase genes among carbapenem-resistant Acinetobacter baumannii blood isolates in Taiwan
- (2018) Teng-Ho Wang et al. Antimicrobial Resistance and Infection Control
- Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals
- (2017) Matthew E. Falagas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacokinetics/pharmacodynamics of systemically administered polymyxin B against Klebsiella pneumoniae in mouse thigh and lung infection models
- (2017) Cornelia B Landersdorfer et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace
- (2017) Latania K. Logan et al. JOURNAL OF INFECTIOUS DISEASES
- Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity againstPseudomonas aeruginosa
- (2016) Akinobu Ito et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-ResistantEnterobacteriaceaeBacteremia
- (2016) Pranita D. Tamma et al. CLINICAL INFECTIOUS DISEASES
- The epidemiology of carbapenemases in Latin America and the Caribbean
- (2016) Kevin Escandón-Vargas et al. Expert Review of Anti-Infective Therapy
- Pharmacodynamic Profiling of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa: Assessing the Risk for Resistance and Attenuated Efficacy
- (2015) Aryun Kim et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins
- (2015) M. Berrazeg et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroAntimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains
- (2015) Naoki Kohira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Epidemiology of Carbapenem-Resistant Enterobacteriaceae in 7 US Communities, 2012-2013
- (2015) Alice Y. Guh et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
- (2014) Rujipas Sirijatuphat et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Involvement of Fe Uptake Systems and AmpC β-Lactamase in Susceptibility to the Siderophore Monosulfactam BAL30072 in Pseudomonas aeruginosa
- (2013) Christian van Delden et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Adaptation-Based Resistance to Siderophore-Conjugated Antibacterial Agents by Pseudomonas aeruginosa
- (2013) Andrew P. Tomaras et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
- (2013) Emanuele Durante-Mangoni et al. CLINICAL INFECTIOUS DISEASES
- Mechanisms of β-lactam Resistance Among Pseudomonas aeruginosa
- (2012) Daniel J. Wolter et al. CURRENT PHARMACEUTICAL DESIGN
- Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia
- (2012) H. AYDEMIR et al. EPIDEMIOLOGY AND INFECTION
- Antibacterial-Resistant Pseudomonas aeruginosa: Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance Mechanisms
- (2009) P. D. Lister et al. CLINICAL MICROBIOLOGY REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now